Intellia Therapeutics is trading at $11.73, down 5.13% on October 7, with the precise driver unconfirmed. - No company announcement specific to October 7 emerged in the reviewed sources. - Barclays initiated coverage on October 6 with an Underweight rating and an $8 price target; evidence does not establish it as the cause. - The supplied data shows XBI down 2.50%, amid pressure from higher yields and caution ahead of the Fed minutes, consistent with a broader risk-off backdrop.